Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: Feb 14, 2025
CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024.
Read more at prnewswire.com
